If you recruit in biopharma, you are working two jobs at the same time.
The first job is managing a surplus. Novartis cut 322 employees at its East Hanover, New Jersey headquarters on July 7, targeting field sales, patient support, and marketing. Genentech disclosed 103 cuts on July 6 as part of a restructuring. Takeda trimmed 243 field-based sales representatives across 47 states, a direct response to the patent cliff approaching on antidepressant Trintellix.
The second job is managing a shortage. Clinical operations directors, regulatory affairs vice presidents, cell and gene therapy CMC leaders, and drug safety physicians are running six to nine months to fill. In some specialties, candidates with the right credentials simply do not exist in large enough numbers to go around.
These two jobs are happening inside the same companies, sometimes inside the same quarter. This is the biopharma barbell of 2026, and if you don't see both ends clearly, you'll misread every search you run in the back half of this year.
Layoffs Are Slowing - But the Cuts Haven't Stopped
The broader layoff picture has improved. FierceBiotech tracked 17 biopharma companies reporting cuts from April through June 2026 - barely half the 33 companies that announced layoffs in Q1. That compares to 64 and 62 announcements in Q2 and Q3 2025, respectively, which marked the peak of the industry's downcycle.
Across healthcare and pharma in 2026, over 14,180 jobs have been cut across more than 25 companies, according to layoff tracking data from LayoffHedge. The single largest cut was Takeda's 4,500-position reduction earlier this year.
The pattern driving most of 2026's cuts is not financial distress. It is strategic repositioning. Patent cliffs, pipeline pivots, and post-M&A consolidation are trimming the commercial and field-facing organizations built around yesterday's approved drugs.
The Takeda situation is the clearest illustration: 243 field reps tied to Trintellix are coming off the payroll while the company simultaneously prepares approximately 400 new commercial roles for its next wave of launches. That is not a company in crisis. That is a company mid-pivot.
The Bench Got Thinner Than Anyone Planned For
The harder problem is not what is being cut. It is what happens when companies need to hire back on the clinical and regulatory side.
During the 2024-2025 biopharma downturn, thousands of life sciences professionals left the industry entirely. Some moved into tech, healthcare services, or consulting. Some retired early or went independent. Biotech absorbed a generation of talent through the pandemic-era expansion, then shed it through two years of retrenchment, and a meaningful share of that talent is not available to come back.
What that means in 2026: the bench is thinner than the pipeline assumes.
Phase 1 and Phase 2 programs are accelerating across the industry. Cell and gene therapy assets are moving toward pivotal trials. Rare disease companies are competing for the same narrow slice of regulatory expertise needed to navigate complex BLAs and NDAs. But the training pipelines that supply those roles contracted during the freeze. Movement across companies slowed. Many people who held these positions two years ago have since settled into new roles or left the field.
Executive search data from Panda International pegs demand for senior cell and gene therapy CMC leaders - Directors and Vice Presidents of Chemistry, Manufacturing, and Controls - at approximately four times the available supply. Searches for this profile, along with VP Regulatory Affairs with first-in-class BLA or NDA experience and CMOs with prior approval credentials, are routinely running six to nine months.
Two Recruiting Markets Under One Industry Label
The barbell creates two distinct talent environments that happen to share the same sector name.
On the commercial side, supply has expanded. Field sales professionals, regional medical science liaisons tied to older products, and patient support staff have been coming to market at higher volumes than 2023 or 2024. If your search is in this category, you have more candidates, more time to be selective, and less compensation pressure than you did 18 months ago. The mistake is assuming this market-level dynamic tells you anything about the clinical and regulatory environment. It doesn't.
On the scientific and regulatory side, conditions are the opposite. Senior clinical operations directors with pivotal-trial experience, regulatory affairs leaders who can run first-in-class submissions, and drug safety physicians with oncology depth are in short supply relative to demand. Companies expecting a 60-to-90-day fill based on prior-cycle benchmarks will find themselves 90 to 180 days off.
There is a digital skills dimension layered on top of both sides. Pharma organizations are embedding AI literacy requirements across functions - from clinical data management to pharmacovigilance to commercial analytics. The Association of the British Pharmaceutical Industry (ABPI) has reported that 43% of pharma companies struggle to find candidates who meet the digital literacy requirements now built into roles across their workforce. U.S. life sciences recruiters describe a similar pattern: candidates who can pass a clinical screen but lack the data tools fluency now expected in the same job description.
The Tactical Mistakes Happening Right Now
Benchmarking fill times against pre-2024 data. The searches that closed in 18 weeks two years ago are running 28 to 36 weeks now, not because the overall market is weaker but because the available talent for senior clinical, CMC, and regulatory roles was always a constrained pool. The candidates who were in motion during 2021-2022 are now settled, often in new roles after the downturn, and far less responsive to outreach.
Treating commercial roles and clinical roles as the same search. A regional oncology sales director search is not the same market as a VP of Clinical Operations with rare disease experience. The sourcing approach, timeline, and comp positioning need to be different. Conflating them means you overshoot on effort for commercial hires and undershoot on urgency for clinical ones.
Assuming displaced talent matches your open roles. When Novartis cuts 322 people from field sales and patient support, it is tempting to source from that pool for similar-looking searches. But the clinical operations and regulatory roles that are hardest to fill are exactly the specialties companies held onto longest during the downturn. The displaced population and the shortage population are not the same people.
Pricing clinical roles against 2022 or 2023 comp data. Compensation expectations for Director-level regulatory affairs, clinical operations, and CMC roles have moved significantly as the pool has narrowed. Posting to market at prior-cycle figures while expecting comparable-quality candidates is not a neutral act - it actively selects against the candidates you most need.
What to Do Before Q3 Closes
Run your open roles against the barbell framework. If the role is commercial, field-based, or product-support oriented, you have more leverage than you think right now. Candidates are available. Use this window to build pipeline for roles that will open when the next launch wave requires those skills.
If the role is clinical operations, regulatory affairs, medical affairs, CMC, or drug safety - treat it as a six-to-nine-month search before the req is even opened. Set that expectation with hiring managers now. Get interim coverage in place if the business cannot absorb a long fill. And price the role against 2025-2026 market data, not what you last paid for a comparable head.
The structural pressure here is not going to ease in the next six months. The Phase 2 pipeline is expanding, which means demand for senior clinical and regulatory talent will keep outpacing supply heading into 2027. The companies that reset their staffing timelines, comp frameworks, and sourcing strategies now will be better positioned when the next cycle of approvals comes through.
The barbell is real. Work both ends.
BlueLine's candidate and compensation data covers life sciences roles by specialty, level, and geography. See current market rates and active talent at bluelinesearch.ai/register.